Conference Introduction
Across two dynamic days in Barcelona, we’ll dive deep into the latest advances in PROTACs, molecular glues, novel ligase targeting, and emerging platforms like LYTACs and DUBTACs. From early discovery to the clinic, the field is evolving rapidly — and this event is your opportunity to stay ahead, form partnerships, and help shape the future of small- molecule precision medicine.
6 Key Themes for the TPD Summit 2025
-
Innovations in Degrader Chemistry: Advancing bifunctional and monovalent degraders: PROTACs, glues, covalent binders
-
Expanding the E3 Ligase Toolbox: Novel ligases, tissue specificity, and targeted degradation strategies
-
Structural Biology & Rational Design: Ternary complex dynamics, modeling, and degrader-enabled selectivity
-
PK/PD, Bioavailability & Drug-Like Properties: Oral delivery, blood–brain barrier access, and degradation kinetics
-
Clinical Translation & Biomarker Strategies: First-in-human studies, pharmacodynamic endpoints, and trial design
- Emerging Modalities in Protein Degradation: LYTACs, AUTACs, DUBTACs, and new frontiers in subcellular targeting
Who Should Attend
- Medicinal Chemists & Structural Biologists: Driving rational degrader design and ligand discovery
- Drug Discovery Scientists & Pharmacologists: Exploring new modalities for undruggable targets
- Biotech & Pharma Executives: Leading R&D, BD, and clinical strategy in TPD programs
- Clinical Development Leaders: Advancing degraders through preclinical and early-phase trials
- Computational Biologists & Platform Engineers: Enabling in silico modeling, AI-driven design, and degrader screening
- Investors & Venture Capitalists: Seeking the next wave of innovation in oncology, neuro, and inflammation
- Regulatory & IP Professionals: Navigating new frameworks for novel mechanisms of action
Industries Represented
- Small Molecule Drug Discovery
- Biopharma & Degrader-Platform Biotech
- Structural & Computational Biology
- CROs & Preclinical Services
- Medicinal & Synthetic Chemistry
- Pharmaceutical IP & Legal
- Venture Capital & Strategic Partnerships
